Dicerna Pharmaceuticals (NASDAQ:DRNA)

CAPS Rating: 3 out of 5

Caps

How do you think DRNA will perform against the market?

Add Stock to CAPS Watchlist

All Players

40 Outperform
4 Underperform
 

All-Star Players

14 Outperform
3 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top DRNA Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

extremereturns (98.23)
Submitted June 29, 2016

Its amazing when a company clearly sets its business plan, research goals, and costs of R&D, and investors and institutional funds love what they here during an IPO, only to have shares fall by over 95% thereafter, when nothing negative, no… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

DRNA VS S&P 500 (SPY)

DRNA Summary

Recent Community Commentary

Read the most recent pitches from players about DRNA.

Recs

0
Member Avatar SmartAce (99.94) Submitted: 10/2/2017 1:25:27 PM : Outperform Start Price: $5.15 DRNA Score: +3.91

My wife wants me to go to Zumba with her. I am hopeful that this is a place to get burritos.

Recs

1
Member Avatar extremereturns (98.23) Submitted: 6/29/2016 2:10:13 PM : Outperform Start Price: $3.20 DRNA Score: +44.58

Its amazing when a company clearly sets its business plan, research goals, and costs of R&D, and investors and institutional funds love what they here during an IPO, only to have shares fall by over 95% thereafter, when nothing negative, no surprises, was ever even reported since the IPO. This was the case with Dicerna Pharmaceuticals (DRNA), and the company traded at $46 a share not that long ago. Dicerna continues to just chug along, moving forward with its proprietary RNA interference technology platform for liver diseases and cancer. The spike in volume yesterday suggests, that possibly the big institutional money may be planning on taking this one back above the IPO price of $46, after all, if Wall Street takes a company from $46 to under $4 on nothing but sentiment, what keeps it from moving right back up again? Maybe the wind will shift and RNA research companies with become a hot commodity once again, I'm taking a chance on that.

Recs

0
Member Avatar oscillation (78.94) Submitted: 5/19/2016 10:39:37 PM : Outperform Start Price: $3.47 DRNA Score: +32.66

nev

Leaderboard

Find the members with the highest scoring picks in DRNA.

Score Leader

mrblond2

mrblond2 (89.43) Score: +95.03

The Score Leader is the player with the highest score across all their picks in DRNA.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
mrblond2 89.43 7/23/2014 Underperform 3M $16.09 -66.00% +29.03% +95.03 0 Comment
seventotheseven < 20 1/3/2017 Outperform 5Y $2.89 +89.27% +14.25% +75.02 0 Comment
Under5 < 20 6/29/2017 Outperform 5Y $3.25 +68.31% +5.11% +63.20 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. ResearchLover 54.31 11/9/2016 Outperform 5Y $3.09 +77.02% +20.16% +56.87 0 Comment
portefeuille 98.72 9/2/2016 Outperform 5Y $3.18 +72.01% +17.19% +54.83 0 Comment
portefeuille2 99.46 9/9/2016 Outperform 5Y $3.18 +72.01% +18.58% +53.44 0 Comment
mistermiranga 99.68 8/26/2016 Outperform 5Y $3.33 +64.26% +17.87% +46.40 0 Comment
extremereturns 98.23 6/28/2016 Outperform 5Y $3.20 +70.94% +26.36% +44.58 1 Comment
jwpao09 34.67 7/18/2016 Outperform 5Y $3.36 +62.80% +18.59% +44.21 0 Comment
beecha 33.60 9/19/2017 Outperform 5Y $4.02 +36.07% +2.44% +33.63 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for DRNA.

Featured Broker Partners